Research Abstract
Our work serves to identify molecular drivers that can inform therapeutic opportunity and to define useful prognostic biomarkers that collectively may help patients towards optimal melanoma treatment. Specifically, using orthogonal analyses of tumor cell metabolism, paralleled with clinical outcome correlates, we currently characterize inherent cues that steer tumor cell vulnerabilities towards each intrinsic; BRAF(V600E)-targeted, and extrinsic; immune checkpoint inhibition agents.
